A Refractory Celiac Patient Successfully Treated With Mesenchymal Stem Cell Infusions

Rachele Ciccocioppo, Alessandra Gallia, Maria A. Avanzini, Elena Betti, Cristina Picone, Alessandro Vanoli, Chiara Paganini, Federico Biagi, Rita Maccario, Gino R. Corazza

Research output: Contribution to journalArticlepeer-review


Type II refractory celiac disease (RCD), as defined according to the amount of aberrant intraepithelial lymphocytes, is a condition characterized by severe malabsorption syndrome and poor prognosis, with no effective treatment. Based on the regenerative and immunomodulatory properties of mesenchymal stem cells (MSCs), we investigated the feasibility, safety, and efficacy of serial infusions of autologous bone marrow-derived MSCs in a 51-year-old woman with type II RCD. Mesenchymal stem cells were isolated, expanded, and characterized following standard protocols. Monitoring of the patient's malabsorption indexes, mucosal architecture, and percentage of aberrant intraepithelial lymphocytes was scheduled for the time of enrollment, at each infusion, and after 6 months. Determination of mucosal expression of interleukin (IL)-15 and its receptor was also performed. Expansion of MSCs was feasible, and the patient underwent 4 systemic infusions of 2 × 106 MSCs/kg body weight 4 months apart, without adverse effects. During the treatment period, she experienced gradual and durable amelioration of her general condition, with normalization of stool frequency, body mass index, laboratory test results, and mucosal architecture. Remarkably, the expression of IL-15 and its receptor almost completely disappeared. Thus, treatment of RCD with serial MSC infusions seems promising, leading to recovery from the life-threatening condition while blocking the IL-15 pathogenic pathway.

Original languageEnglish
JournalMayo Clinic Proceedings
Publication statusAccepted/In press - 2016

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'A Refractory Celiac Patient Successfully Treated With Mesenchymal Stem Cell Infusions'. Together they form a unique fingerprint.

Cite this